Suboptimal choices and dosing of statins at start of therapy

British Journal of Clinical Pharmacology

Volumn 60, Issue 1, 2005, Pages 83-89

  Mantel Teeuwisse, Aukje K ^a   Klungel, Olaf H ^a   Schalekamp, Tom ^a   Verschuren, W M Monique ^b   Porsius, Arijan J ^a   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Interactions; Pharmacotherapy; Quality; Statins

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; INSULIN; LOOP DIURETIC AGENT; MACROLIDE; MIBEFRADIL; NEFAZODONE; NITRATE; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; SIMVASTATIN; STATINE DERIVATIVE; VERAPAMIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DATA BASE; DIABETES MELLITUS; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG METABOLISM; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PHARMACY; PRIORITY JOURNAL; QUALITY CONTROL; RHABDOMYOLYSIS;

CHOICE BEHAVIOR; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF HEALTH CARE;

EID: 21744439178     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02367.x     Document Type: Article

References (28)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
2. Ross SD, Allen IE, Connelly JE et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999; 159: 1793-1802.
3. Bevilacqua M, Bettica P, Milani M et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79: 84-87.
4. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678-682.
5. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-587.
6. Stein E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol 1998; 82: 40J-46J.
7. Jukema JW, Simoons ML. Treatment and prevention of coronary heart disease by lowering serum cholesterol levels; from the pioneer work of C.D. de Langen to the third 'Dutch Consensus on Cholesterol'. Acta Cardiol 1999; 54: 163-168.
8. Anonymous. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-1503.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
10. Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in The Netherlands. [Thesis]. Utrecht: Utrecht University, 1993.
11. World Health Organization. Guidelines for ATC Classification and DDD Assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology - Nordic Council on Medicines, 1999.
12. Prueksaritanont T, Zhao JJ, Ma B et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042-1051.
13. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690.
14. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63: 367-378.
15. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-428.
16. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
17. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
18. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin and simvastatin. Lancet 1994; 343: 1554-1555.
19. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341.
20. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000; 68: 391-400.
21. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-1107.
22. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-182.
23. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2: 205-207.
24. Derijks HJ, De Koning GH, Mantel-Teeuwisse AK, Egberts AC. Limited adherence to safety instructions in drug leaflets. Br J Clin Pharmacol 2002; 54: 678-679.
25. Cabana MD, Rand CS, Powe NR et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458-1465.
26. Thomas S, Van der Weijden T, Van Drenth BB, Haverkort AFM, Hooi JD, Van der Laan JD. NHG-standaard cholesterol [in Dutch]. Huisarts Wet 1999; 42: 406-417.
27. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000; 283: 373-380.
28. Thomson O'Brien MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Harvey EL. Educational outreach visits: effects on professional practice and health care outcomes (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester: John Wiley & Sons, 2003.